1. Table of Contents
1.1 List of Tables
1.2 List of Figures

2. Yellow Fever Pipeline Trends and Insights
2.1 Dominant Phase type of Yellow Fever Pipeline, 2020
2.2 Most focused Mechanism of Action in Yellow Fever Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Yellow Fever pipeline
2.5 Active Companies Developing Yellow Fever pipeline

3. Yellow Fever Disease Types, Symptoms, Causes, and Available Treatment Options
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options

4. Yellow Fever Pipeline Company Trends and Insights- Business Profiles, Drug Candidates and Contacts
4.1 Bavarian Nordic A/S
- BioCryst Pharmaceuticals Inc
- Curevac AG
- Emergex Vaccines Ltd
- Ennaid Therapeutics LLC
- Fab'entech SA
- iBio Inc
- Imutex Ltd
- Medigen Inc
- Najit Technologies Inc
- Sanofi
- Tychan Pte Ltd

5. Yellow Fever Pipeline Drug Profiles
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details

6. Yellow Fever Pipeline Market News and Developments during 2020

7. Appendix
7.1 About the Publisher
7.2 Sources and Research Methodology

Companies mentioned
Bavarian Nordic A/S, BioCryst Pharmaceuticals Inc, Curevac AG, Emergex Vaccines Ltd, Ennaid Therapeutics LLC, Fab'entech SA, iBio Inc, Imutex Ltd, Medigen Inc, Najit Technologies Inc, Sanofi, Tychan Pte Ltd